Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Cyber Monday 2025: Save over 70% on HBO Max with this Prime Video streaming deal - 2Do-It-Yourself Home Style on a Careful spending plan: Imaginative Thoughts and Tasks
- 3Manual for Notorious Fragrances: Immortal Aromas
- 4‘Harry Potter and the Philosopher’s Stone’ trailer is raising eyebrows among Potterheads: ‘Where’s the whimsical color?’
- 5Authorities arrest 7 bodyguards in connection with a Mexican mayor's assassination
- Share your pick for the tree that you love for its novel magnificence!
- IDF, police arrest eleven for criminal, terror-related activity over weekend
- Which camera do you believe is great for first-time clients? !
- Countdown to Artemis II: What to know about NASA's moon mission
- Beating Scholastic Difficulties: Understudy Examples of overcoming adversity
- More parents refusing vitamin K shots for newborns, study finds
- Getting breast implants was a mistake I live with every day. Why I’m sharing my story now, at 70, in pain and afraid.
- Fundamental Venture The board Apparatuses for Remote Groups
- Alice Wong, founder of the Disability Visibility Project, dies at 51
